Paper36765622
Clear Cell Renal Cell Carcinoma: From Biology to Treatment.
Kase AM and 2 others. Cancers (Basel), 2023. Cited by 78 papers, by iCite.
Cite this record
ConductScience Library. Clear Cell Renal Cell Carcinoma: From Biology to Treatment. Papers, record 36765622. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36765622
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References86
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 29860937 | Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell Carcinoma. | N Engl J Med | 2018 | https://conductscience.org/library/papers/29860937 | PubMed |
| 2 | 20368553 | Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. | J Clin Oncol | 2010 | https://conductscience.org/library/papers/20368553 | PubMed |
| 3 | 3055163 | Interferon therapy of metastatic renal cell cancer. | Semin Surg Oncol | 1988 | https://conductscience.org/library/papers/3055163 | PubMed |
| 4 | 32306075 | Tumor-infiltrating CD39+CD8+ T cells determine poor prognosis and immune evasion in clear cell renal cell carcinoma patients. | Cancer Immunol Immunother | 2020 | https://conductscience.org/library/papers/32306075 | PubMed |
| 5 | 291749 | Effect of host immune capability on radiocurability and subsequent transplantability of a murine fibrosarcoma. | J Natl Cancer Inst | 1979 | https://conductscience.org/library/papers/291749 | PubMed |
| 6 | 31371341 | PD-L1 Expression and Clinical Outcomes to Cabozantinib, Everolimus, and Sunitinib in Patients with Metastatic Renal Cell Carcinoma: Analysis of the Randomized Clinical Trials METEOR and CABOSUN. | Clin Cancer Res | 2019 | https://conductscience.org/library/papers/31371341 | PubMed |
| 7 | 27974689 | PD-1 and its ligands are important immune checkpoints in cancer. | Oncotarget | 2017 | https://conductscience.org/library/papers/27974689 | PubMed |
| 8 | 21436444 | Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. | Science | 2011 | https://conductscience.org/library/papers/21436444 | PubMed |
| 9 | 33657295 | Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma. | N Engl J Med | 2021 | https://conductscience.org/library/papers/33657295 | PubMed |
| 10 | 31377159 | Stereotactic Ablative Radiation Therapy (SAbR) Used to Defer Systemic Therapy in Oligometastatic Renal Cell Cancer. | Int J Radiat Oncol Biol Phys | 2019 | https://conductscience.org/library/papers/31377159 | PubMed |
| 11 | 26482279 | Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial. | Lancet Oncol | 2015 | https://conductscience.org/library/papers/26482279 | PubMed |
| 12 | 14043685 | SPONTANEOUS REGRESSION OF PULMONARY METASTASES SECONDARY TO CARCINOMA OF KIDNEY. | Br J Dis Chest | 1963 | https://conductscience.org/library/papers/14043685 | PubMed |
| 13 | 26406150 | Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma. | N Engl J Med | 2015 | https://conductscience.org/library/papers/26406150 | PubMed |
| 14 | 26406148 | Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. | N Engl J Med | 2015 | https://conductscience.org/library/papers/26406148 | PubMed |
| 15 | 25410406 | Inhibition of the VEGF/VEGFR pathway improves survival in advanced kidney cancer: a systematic review and meta-analysis. | Curr Drug Targets | 2015 | https://conductscience.org/library/papers/25410406 | PubMed |
| 16 | 23964934 | Pazopanib versus sunitinib in metastatic renal-cell carcinoma. | N Engl J Med | 2013 | https://conductscience.org/library/papers/23964934 | PubMed |
| 17 | 30679806 | Interferons α and β in cancer: therapeutic opportunities from new insights. | Nat Rev Drug Discov | 2019 | https://conductscience.org/library/papers/30679806 | PubMed |
| 18 | 33616314 | Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma. | N Engl J Med | 2021 | https://conductscience.org/library/papers/33616314 | PubMed |
| 19 | 20100962 | Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. | J Clin Oncol | 2010 | https://conductscience.org/library/papers/20100962 | PubMed |
| 20 | 16985675 | Paraneoplastic syndromes in urologic malignancy: the many faces of renal cell carcinoma. | Rev Urol | 2002 | https://conductscience.org/library/papers/16985675 | PubMed |
Cited by64
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 78 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42952722 | FN1 promotes invasion of RCC via YWHAZ-associated signaling with partial involvement of the PI3K-Akt pathway. | Front Oncol | 2026 | https://conductscience.org/library/papers/42952722 | PubMed |
| 42914499 | Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with renal cell carcinoma. | ESMO Open | 2026 | https://conductscience.org/library/papers/42914499 | PubMed |
| 42769428 | Promoter Hypermethylation-Driven NPHS2 Silencing Promotes Immune Escape and Sunitinib Resistance in Clear Cell Renal Cell Carcinoma. | Oncol Res | 2026 | https://conductscience.org/library/papers/42769428 | PubMed |
| 42758284 | Quantitative MRI for World Health Organisation/International Society of Urological Pathology Grading of Renal Cell Carcinoma: a systematic review and diagnostic meta-analysis. | Eur Radiol | 2026 | https://conductscience.org/library/papers/42758284 | PubMed |
| 42614232 | Clinicopathological significance and exploratory prognostic modeling of USP18 and YBX3 expression in clear cell renal cell carcinoma: a retrospective Chinese cohort study. | Front Oncol | 2026 | https://conductscience.org/library/papers/42614232 | PubMed |
| 42528652 | Beyond angiogenesis: integrating ferroptosis and metabolic rewiring for next-generation RCC therapy. | Front Oncol | 2026 | https://conductscience.org/library/papers/42528652 | PubMed |
| 42502300 | Single-Cell and Machine Learning Analyses Identify MYDGF as an Immune-Related Biomarker Associated With the Tumor Microenvironment in Clear Cell Renal Cell Carcinoma. | Hum Mutat | 2026 | https://conductscience.org/library/papers/42502300 | PubMed |
| 42449597 | Chimeric Antigen Receptor-Immune Cell-Based Therapies for Clear Cell Renal Cell Carcinoma: Latest Advancements and Directions. | Cancers (Basel) | 2026 | https://conductscience.org/library/papers/42449597 | PubMed |
| 42440216 | Prospective evaluation of 18F-PSMA-1007 PET/CT in renal masses paired with PSMA immunohistochemistry. | Ann Nucl Med | 2026 | https://conductscience.org/library/papers/42440216 | PubMed |
| 42278578 | From Genes to Proteins: The Indispensable Role of Proteogenomics in Advancing Clear Cell Renal Cell Carcinoma Research. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/42278578 | PubMed |
| 42278450 | De Novo Lipogenesis in Clear Cell Renal Cell Carcinoma: Mechanistic Insights and Therapeutic Implications. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/42278450 | PubMed |
| 42199341 | SLC40A1 (iron transporter): mechanistic regulation, role in disease pathogenesis, and prospects for targeted therapy. | Front Cell Dev Biol | 2026 | https://conductscience.org/library/papers/42199341 | PubMed |
| 42138077 | Metastatic tropism of molecularly defined clear-cell renal cell carcinoma clusters. | J Clin Invest | 2026 | https://conductscience.org/library/papers/42138077 | PubMed |
| 42111157 | USP18 promotes clear cell renal cell carcinoma progression by regulating the ubiquitination and stability of YBX3. | iScience | 2026 | https://conductscience.org/library/papers/42111157 | PubMed |
| 42004076 | PIM1 expression is prognostic in clear cell renal cell carcinoma and influenced by an IL-6/JAK/STAT axis. | Am J Cancer Res | 2026 | https://conductscience.org/library/papers/42004076 | PubMed |
| 41779200 | Activation of the PI3K/AKT pathway by EDIL3 induces EMT and promotes tumor progression in clear cell renal cell carcinoma. | Mol Genet Genomics | 2026 | https://conductscience.org/library/papers/41779200 | PubMed |
| 41519750 | Comprehensive analysis of key palmitoylation-modifying enzymes in clear cell renal cell carcinoma: implications for prognosis and therapy. | Cancer Cell Int | 2026 | https://conductscience.org/library/papers/41519750 | PubMed |
| 41399267 | Prognostic and Therapeutic Potential of Nicotinamide N-Methyltransferase and Hypoxia Inducible Lipid Droplet Associated in Clear Cell Renal Cell Carcinoma. | J Korean Med Sci | 2025 | https://conductscience.org/library/papers/41399267 | PubMed |
| 41346582 | R3HDM4 influences kidney renal clear cell carcinoma progression, immune modulation, and potential links to the IGSF8 immune checkpoint. | Front Immunol | 2025 | https://conductscience.org/library/papers/41346582 | PubMed |
| 41295556 | Clinical-Oriented Hierarchical Machine Learning Framework for Early Kidney Tumor Detection and Malignant Subtype Classification. | Tomography | 2025 | https://conductscience.org/library/papers/41295556 | PubMed |
Genes41
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/36765622
GET https://conductscience.org/api/papers/v1/36765622/references?page=2